MedTrace Logo

99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization

NCT03546478 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-06-06

No results posted yet for this study

Summary

This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the diagnostic performance and evaluation efficacy of 99mTc-ABH2 in breast cancer patients. A single dose of 370±54 Mega-Becquerel (MBq)99mTc-ABH2 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.

Conditions

Interventions

BIOLOGICAL

99mTc-ABH2

99mTc-ABH2 were injected into the patients before the SPECT/CT scans

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Fang Li, MD · Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical Colleg

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
29 Years
Max Age
76 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-24
Primary Completion
2017-05-24
Completion
2018-05-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03546478 on ClinicalTrials.gov